Klin Farmakol Farm. 2015;29(1):13-15

Pharmacotherapy of advanced or metastatic bladder cancer

Jana Katolická
Onkologicko-chirurgické oddělení, FN u sv. Anny, Brno

Bladder cancer is the ninth most commonly diagnosed malignancy among all cancers worldwide. Chemotherapy in treating advanced

and metastatic bladder cancer has been established as a standard therapeutic method. Cisplatin-based regimens achieve high response

rates. Gemcitabine with cisplatin is a standard chemotherapy regimen for the first-line treatment of metastatic urothelial bladder cancer.

Vinflunine is recommended for administration in the second line in patients with metastatic urothelial bladder cancer following the

failure of previous treatment with a platinum derivative.

Keywords: metastatic bladder cancer, chemotherapy, M-VAC, gemcitabine/cisplatin, vinflunine

Published: March 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Katolická J. Pharmacotherapy of advanced or metastatic bladder cancer. Klin Farmakol Farm. 2015;29(1):13-15.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Minčík I. Diagnostika nádorov močového mechúra. Česká urologie 2009; 13(1): 43-60.
    2. Vařechová K, Povová J, Janout V. Epidemiologie karcinomu močového měchýře. Urol. praxi, 2013; 14(3): 104-108.
    3. Katolická J. Chemoterapie u invazivního a metastatického karcinomu nádorů močového měchýře. Urol list 2011; 9(3): 40-45.
    4. Sternberg CN, Yagoda A, Scher HI, et al. Methotrexate, vinblastine, doxorubicin and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 1989; 64(12): 2448-2458. Go to original source...
    5. Loehrer PJ Sr, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatina loneor in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992; 10(7): 1066-1073. Go to original source... Go to PubMed...
    6. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatine versus methotrexate, vinblastine, doxorubicin and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000; 18(17): 3068-3077. Go to original source... Go to PubMed...
    7. Logothetis CJ, DexeusFH, Finn L, et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urotelial tumors. J Clin Oncol. 1990; 8(6): 1050-1055. Go to original source... Go to PubMed...
    8. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin with methotrexate, vinblastine, doxorubicin plus cisplatin in patients with bladder cancer. J Clin Oncol 2005; 23(21): 4602-4608. Go to original source...
    9. Dreicer R, Manola J, Roth BJ, et al. Phase III trial methotrexate, vinblastine, doxorubicin and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of urotelium. Cancer. 2004; 100(8): 1639-1645. Go to original source...
    10. Hahn NM, Stadler WM, Zon R, et al. Mature results from Hoosier Oncology Group GU 04-75phase II trial of cisplatin (C), gemcitabine (G) and bevacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma (UC). American Socienty of Clinical Oncology Annual Meeting: 2010. Chicago, IL. Go to original source...
    11. Hussain RS, Vaishampayan U, DU W, Redman B, Smith DC. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol. 2001; 19(9): 2527-2533. Go to original source...
    12. Johnson P, Geldart T, Fumoleau P, Pinel MC, Nguyen L, Judson I. Phase I study ofvinflunineadministered as a 10-minutes infusion on days 1 and 8 every 3 weeks. Invest New Drugs. 2006; 24(3): 223-231. Go to original source...
    13. Culine S, Theodore C, De Santis M, et al. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer. 2006; 94(10): 1395-1401. Go to original source... Go to PubMed...
    14. Vaughn DJ, Srinivas S, Stadler WM, et al. Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study. Cancer. 2009; 115(18): 4110-4117. Go to original source...
    15. Javlor 25 mg/ml concentrate for solution for infusion: summary of product charakteristics. London: European Medicines Agency, 2011 Nov 10.

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.